Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Study sponsor: Scynexis, Inc. · SCYX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-06Actual
Enrollment · participants27Actual
Source updated2024-06-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.